Categories AlphaGraphs, Earnings, Health Care

A visual dashboard of Amgen’s (AMGN) Q1 2020 earnings results

Amgen’s (NASDAQ: AMGN) top and bottom line in the first quarter of 2020 beat analysts’ estimates. The biotech firm’s adjusted earnings per share surged 17% to $4.17, driven by increased revenues and fewer weighted-average shares outstanding. Revenue rose 11% annually to $6.2 billion. AMGN stock was trading up about 1% during the extended-hours.

GAAP earnings per share decreased 3% to $3.07 in the first quarter. Product sales increased 12% globally, driven by volume growth across a number of Amgen’s newer products.

Amgen (AMGN) Q1 2020 Earnings Infograph

Amgen reaffirmed its 2020 revenue guidance of $25.0 billion to-$25.6 billion. GAAP EPS guidance was revised to a range of $10.65 to $11.45 and the company maintained the non-GAAP EPS outlook of $14.85-$15.60.

Amgen announced that Otezla, an oral treatment approved in more than 50 countries for inflammatory diseases such as psoriasis and psoriatic arthritis, will be investigated as a potential immunomodulatory treatment in adult patients with COVID-19 in upcoming platform trials.

Most Popular

Mattel (MAT): A look at the toymaker’s expectations for the year

Shares of Mattel, Inc. (NASDAQ: MAT) were up slightly on Thursday. The stock has gained 20% year-to-date and 19% over the past three months. There is a level of optimism

Earnings Preview: Paychex likely to report higher Q1 revenue and profit

Paychex Inc. (NASDAQ: PAYX), a leading provider of human capital management solutions, is all set to publish operating results for the first three months of fiscal 2024. The company has

DRI Earnings: Key quarterly highlights from Darden Restaurants’ Q1 2024 financial results

Darden Restaurants, Inc. (NYSE: DRI) reported first quarter 2024 earnings results today. Total sales increased 11.6% to $2.73 billion compared to the same period last year. Blended same-restaurant sales were

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top